Optimal antiviral switching to minimize resistance risk in HIV therapy

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Luo, Rutao ^a   Piovoso, Michael J ^b   Martinez Picado, Javier ^c,d   Zurakowski, Ryan ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Institut de Recerca de la SIDA IrsiCaixa   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE INHIBITOR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TENOFOVIR; VIRUS PROTEIN; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBIOTIC RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; GENETIC DISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; NONHUMAN; RISK REDUCTION; STATISTICAL MODEL; VIRUS LOAD; VIRUS STRAIN; ANTIVIRAL RESISTANCE; DRUG EFFECT; GENETICS; VIROLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 80455174313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027047     Document Type: Article

References (39)

1. Gray C, Lawrence J, Ranheim E, Vierra M, Zupancic M, et al. (2000) Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. AIDS Res Hum Retroviruses 16: 1357-1369.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
3. Ribeiro RM, Bonhoeffer S, (2000) Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci USA 97: 7681-7686.
4. Ribeiro R, Mohri H, Ho D, Perelson A, (2002) In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A 99: 15572-15577.
5. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, et al. (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296: 827-843.
6. Deeks S, Wrin T, Liegler T, Hoh R, Hayden M, et al. (2001) Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New Engl J Med 344: 472-480.
7. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, et al. (2003) Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17: 361-370.
8. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, et al. (2005) Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 192: 1537-1544.
9. Ghosn J, Wirden M, Ktorza N, Peytavin G, Aït-Mohand H, et al. (2005) No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 19: 1643-1647.
10. Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, et al. (2006) A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis 194: 1309-1318.
11. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, et al. (2004) Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 18: 217-226.
12. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, et al. (2003) Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349: 837-846.
13. Bonjoch A, Buzon MJ, Llibre JM, Negredo E, Puig J, et al. (2008) Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated. HIV clinical trials 9: 387-398.
14. Martinez-Picado J, Negredo E, Ruiz L, Shintani A, Fumaz CR, et al. (2003) Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med 139: 81-89.
15. Mansky LM, (1996) Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. AIDS Res Hum Retroviruses 12: 307-314.
16. Shafer RW, (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194 (Suppl 1): S51-8.
17. Bonhoeffer S, Nowak MA, (1997) Pre-existence and emergence of drug resistance in HIV-1 infection. Proc Biol Sci 264: 631-637.
18. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, et al. (1994) Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 68: 7467-7481.
19. Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, et al. (1996) Genetic characterization of human immunode_ciency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 70: 3098-3107.
20. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, et al. (1997) In vivo compartmentalization of human immunode_ciency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 71: 2059-2071.
21. Colgrove R, Japour A, (1999) A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Res 41: 45-56.
22. Ruiz L, Carcelain G, Martínez-Picado J, Frost S, Marfil S, et al. (2001) HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 15: F19-27.
23. Huang Y, Liu D, Wu H, (2006) Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics 62: 413-423.
24. Zurakowski R, Wodarz D, (2007) Treatment interruptions to decrease risk of resistance emerging during therapy switching in HIV treatment. Proc. of the 46th IEEE Conference on Decision and Control New Orleans, LA pp. 5174-5179.
25. Luo R, Zurakowski R, (2008) A new strategy to decrease risk of resistance emerging during therapy switching in HIV treatment. Proc. of the American Control Conference Seattle, WA pp. 2112-2117.
26. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555-570.
27. Luo R, Piovoso M, Zurakowski R, (2010) Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching. Proc. of the American Control Conference Baltimore, MD pp. 5155-5160.
28. Luo R, Cannon L, Hernandez J, Piovoso MJ, Zurakowski R, (2011) Controlling the evolution of resistance. Journal of Process Control 21: 367-378.
29. Luo R, Piovoso M, Zurakowski R, (2009) A generalized multi-strain model of HIV evolution with implications for drug-resistance management. Proc. of the American Control Conference St. Louis, MO pp. 2295-2300.
30. Ananworanich J, Nuesch R, Braz ML, Chetchotisakd P, Vibhagool A, et al. (2003) Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 17: F33-7.
31. Wodarz D, (2001) Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance. J Theor Biol 213: 447-459.
32. Lifson J, Rossio J, Arnaout R, Li L, Parks T, et al. (2000) Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol 74: 2584-2593.
33. Lifson JD, Rossio JL, Piatak M, Parks T, Li L, et al. (2001) Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 75: 10187-10199.
34. Zurakowski R, (2011) Nonlinear observer output-feedback MPC treatment scheduling for HIV. Biomed Eng Online 10: 40.
35. Thomas JA, Ott DE, Gorelick RJ, (2007) Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions. J Virol 81: 4367-4370.
36. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, et al. (2010) Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84: 2913-2922.
37. Rosero-Garcia E, Zurakowski R, (2010) Closed-loop minimal sampling method for determining viral-load minima during switching. Proc. of the American Control Conference Baltimore, MD pp. 460-461.
38. Cardozo EF, Zurakowski R, (2011) Measurement error robustness of a closed-loop minimal sampling method for HIV therapy switching. Proc. of the IEEE Eng. Medicine and Biology Conference Boston, MA pp. 116-119.
39. Zurakowski R, Churgin M, Perez C, Rodriguez M, (2011) Approximate-model closed-loop minimal sampling method for HIV viral-load minima detection. Proc. of the American Control Conference San Francisco, CA pp. 5418-5419.